135 related articles for article (PubMed ID: 19203540)
1. Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
Henke MM; Richly H; Drescher A; Grubert M; Alex D; Thyssen D; Jaehde U; Scheulen ME; Hilger RA
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):58-60. PubMed ID: 19203540
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Lentz F; Drescher A; Lindauer A; Henke M; Hilger RA; Hartinger CG; Scheulen ME; Dittrich C; Keppler BK; Jaehde U;
Anticancer Drugs; 2009 Feb; 20(2):97-103. PubMed ID: 19209025
[TBL] [Abstract][Full Text] [Related]
3. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
[TBL] [Abstract][Full Text] [Related]
4. KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Hartinger CG; Jakupec MA; Zorbas-Seifried S; Groessl M; Egger A; Berger W; Zorbas H; Dyson PJ; Keppler BK
Chem Biodivers; 2008 Oct; 5(10):2140-2155. PubMed ID: 18972504
[TBL] [Abstract][Full Text] [Related]
5. KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.
Jakupec MA; Arion VB; Kapitza S; Reisner E; Eichinger A; Pongratz M; Marian B; Graf von Keyserlingk N; Keppler BK
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):595-6. PubMed ID: 16372531
[No Abstract] [Full Text] [Related]
6. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
Bijelic A; Theiner S; Keppler BK; Rompel A
J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
[TBL] [Abstract][Full Text] [Related]
8. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
[TBL] [Abstract][Full Text] [Related]
9. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
[TBL] [Abstract][Full Text] [Related]
10. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
11. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
Groessl M; Hartinger CG; Polec-Pawlak K; Jarosz M; Keppler BK
Electrophoresis; 2008 May; 29(10):2224-32. PubMed ID: 18512673
[TBL] [Abstract][Full Text] [Related]
12. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).
Hummer AA; Heffeter P; Berger W; Filipits M; Batchelor D; Büchel GE; Jakupec MA; Keppler BK; Rompel A
J Med Chem; 2013 Feb; 56(3):1182-96. PubMed ID: 23282017
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
Bergamo A; Sava G
Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
Bytzek AK; Koellensperger G; Keppler BK; G Hartinger C
J Inorg Biochem; 2016 Jul; 160():250-5. PubMed ID: 26993078
[TBL] [Abstract][Full Text] [Related]
17. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
18. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
[TBL] [Abstract][Full Text] [Related]
19. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
20. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient.
Hartinger CG; Hann S; Koellensperger G; Sulyok M; Groessl M; Timerbaev AR; Rudnev AV; Stingeder G; Keppler BK
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):583-5. PubMed ID: 16372526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
